AVTX — Avalo Therapeutics Inc · P/E 0.0, $51.5M cap

Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.

Latest reported AVTX revenue for 2025-09-30 was $0. Net income was -$30.6M. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.

Use this AVTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AVTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AVTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Avalo Therapeutics Inc even when a live quote feed is slow.

Avalo Therapeutics Inc latest statements (FY2025)

Latest cached year on this hub. Full AVTX income, balance, and cash tables.

  • Revenue$59.0K
  • Net Income-$78.3M
  • Total Assets$116.5M
  • Total Debt$0
  • Free Cash Flow$0

AVTX recent filings